Mikkel Østergaard

30.6k citations
563 papers · 18.4k · 6 hit papers · h-index 70

Impact in

  • Rheumatology top 0.01%
    • Rheumatoid Arthritis Research and Therapies
    • Spondyloarthritis Studies and Treatments
    • Systemic Lupus Erythematosus Research
    • Musculoskeletal synovial abnormalities and treatments
    • Bone and Joint Diseases

Papers in

    • Rheumatoid Arthritis Research and Therapies 320
    • Spondyloarthritis Studies and Treatments 202
    • Systemic Lupus Erythematosus Research 42
    • Musculoskeletal synovial abnormalities and treatments 39
    • Bone and Joint Diseases 70

Mikkel Østergaard

543 papers receiving 18.0k citations

Mikkel Østergaard's Hit Papers

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study 2018 · 288 citations
2880+7+15Years since publication200400600

Peers

Mikkel Østergaard
Comparison fields: 5 of 146
  • Rheumatology 14.0k
  • Orthopedics and Sports Medicine 1.8k
  • Hematology 2.3k
  • Immunology 2.2k
  • Rehabilitation 251
Replace Maxime Dougados with:
Maxime Dougados France
Robert Landewé Netherlands
Walter P. Maksymowych Canada
Maxime Dougados France
Maria Antonietta D’Agostino France
Joachim Listing Germany
Alain Saraux France
Sjef van der Linden Netherlands
Philip Helliwell United Kingdom
Annamaria Iagnocco Italy
Mikkel Østergaard relative to Maxime Dougados France Maxime Dougados's profile →
Citations per field
00.5×1.5×
Maxime Dougados · 1×
Citations per year

Countries citing papers authored by Mikkel Østergaard

Since Specialization
Citations

This map shows the geographic impact of Mikkel Østergaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikkel Østergaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikkel Østergaard more than expected).

Fields of papers citing papers by Mikkel Østergaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikkel Østergaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikkel Østergaard. The network helps show where Mikkel Østergaard may publish in the future.

Co-authors

The 25 scholars most cited alongside Mikkel Østergaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mikkel Østergaard Line = papers co-authored together Mikkel Østergaard links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 563 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group
Hit paper breakdown →
2009656
2
OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system.
Hit paper breakdown →
2003604
3
Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis
Hit paper breakdown →
2003562
4
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
Hit paper breakdown →
2013462
5
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
Hit paper breakdown →
2009423
6 2004303
7
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Hit paper breakdown →
2018288
8 2008267
9 2010249
10 2005227
11 1997202
12 2006200
13 1998198
14 2012196
15
Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis.
2008189
16 2010187
17 2006182
18 2010175
19 2010169
20 2007163

About Mikkel Østergaard

Mikkel Østergaard is a scholar working on Rheumatology, Orthopedics and Sports Medicine, Immunology, Hematology and Surgery, having authored 563 papers that have together received 18.4k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (320 papers), Spondyloarthritis Studies and Treatments (202 papers), Bone and Joint Diseases (70 papers), Systemic Lupus Erythematosus Research (42 papers), Musculoskeletal synovial abnormalities and treatments (39 papers), Autoimmune and Inflammatory Disorders Research (37 papers), Psoriasis: Treatment and Pathogenesis (34 papers) and Spine and Intervertebral Disc Pathology (14 papers). The work is most often cited by research in Rheumatology (14.0k citations), Orthopedics and Sports Medicine (1.8k citations), Hematology (2.3k citations), Immunology (2.2k citations) and Rehabilitation (251 citations). Mikkel Østergaard has collaborated with scholars based in Denmark, United States and United Kingdom. Frequent co-authors include Susanne Juhl Pedersen, Merete Lund Hetland, Marcin Szkudlarek, Philip G. Conaghan, R. Lambert, Mette Klarlund, Bo Ejbjerg, Walter P. Maksymowych, Henrik S. Thomsen and Michel Court‐Payen. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, Lara D. Veeken, Arthritis Research & Therapy and Scandinavian Journal of Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact